Results 161 to 170 of about 1,562,206 (187)

Utilization Patterns of Nebulized Glycopyrronium in Patients Hospitalized for Acute Exacerbations of Obstructive Airway Disease (AEOAD)-Indian Expert Perspectives. [PDF]

Adv Respir Med
Khanna A, Waghray P, Singh AK, Mehta J, Rithik, Bhagat S, Patil S, Barkate H.   +7 more
europepmc   +1 more source

A Novel PCD Phenotype: Inherent Mucus Hypersecretion by Patient-Derived Airway Epithelial Cells. [PDF]

Pediatr Pulmonol
Castlen J, Leon M, Wright S, Gaston B, Smith L, Davis MD, Norlander A, Tilston-Lunel A.   +7 more
europepmc   +1 more source

Deciphering the Benefits and Risks of Single-Inhaler Triple Therapy in COPD. [PDF]

Adv Respir Med
Kopitovic I, Dimic-Janjic S, Stjepanovic M, Hromis S, Zvezdin B, Ilic MP, Kolarov V, Milic R, Cekerevac I, Cupurdija V, Buha I, Jankovic J, Omcikus M, Trboljevac N, Stankovic I, Vukoja M.   +15 more
europepmc   +1 more source

Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study. [PDF]

Am J Respir Crit Care Med
Lugogo NL, Akuthota P, Sumino K, Burnette AF, Mathur SK, Lindsley AW, Llanos JP, Marchese C, Ambrose CS, Emmanuel B.   +9 more
europepmc   +1 more source

Real-World Phenotypic Profiles and Longitudinal Lung Function Outcomes in Severe Asthma Treated with Biologic Therapies. [PDF]

J Pers Med
Kotsiou OS, Barkas GI, Gourgoulianis KI, Daniil Z.   +3 more
europepmc   +1 more source

Benefits of three consecutive sputum inductions using nebulized racemic salbutamol versus hypertonic saline in smear-negative or sputum-scarce pulmonary tuberculosis patients: a prospective randomized, double-blind study. [PDF]

Microbiol Spectr
Keeratichananont W, Keeratichananont S, Ubonsutvanich N, Chaisurote J.   +3 more
europepmc   +1 more source

Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review. [PDF]

Int J Chron Obstruct Pulmon Dis
Brightling CE, Rabe KF, Singh D, Han MK, Bhutani M, Bourbeau J, Nair P, Drummond MB, Gandhi EA, Sindhwani NS, Molfino NA, Parulekar AD, Ponnarambil SS.   +12 more
europepmc   +1 more source

Monoclonal antibody therapy in patients with severe asthma and COPD: rethinking treatment pathways and success. [PDF]

BMJ Open Respir Res
Burton R, Puthoor M, Fyles F, Lewis L, Joplin H, Burhan H.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The ‘clinically significant’ bronchodilator responsiveness (BDR) in children: a comparative study between six definitions of scholarly societies and a mini-review

Expert Review of Respiratory Medicine, 2021
Helmi Ben Saad, Mohamed Bougrida
exaly  

Acute bronchodilator responses to β2-agonist and anticholinergic agent in COPD: Their different associations with exacerbation

Respiratory Medicine, 2017
Satoshi Konno, Masaru Suzuki, Kaoruko Shimizu   +2 more
exaly